-
Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Njotu, F. N., Ketchemen, J. P., Tikum, A. F., Babeker, H., Gray, B. D., Pak, K. Y., Uppalapati, M., Fonge, H.
Visual Abstract
-
An 18F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Maria Thor, Chen Lee, Lian Sun, Purvi Patel, Aditya Apte, Milan Grkovski, Annemarie F. Shepherd, Daphna Y. Gelblum, Abraham J. Wu, Charles B. Simone, Jamie E. Chaft, Andreas Rimner, Daniel R. Gomez, Joseph O. Deasy, Narek Shaverdian
Visual Abstract
-
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Kyeara N. Mack, Zachary V. Samuels, Lukas M. Carter, Tara D. Viray, Komal Mandleywala, Cory L. Brooks, Michael A. Hollingsworth, Prakash Radhakrishnan, Jason S. Lewis
Visual Abstract
-
[18F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Joanna C. Porter, Balaji Ganeshan, Thida Win, Francesco Fraioli, Saif Khan, Manuel Rodriguez-Justo, Raymond Endozo, Robert I. Shortman, Luke R. Hoy, Toby M. Maher, Ashley M. Groves
Visual Abstract
-
Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies? J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Laura Providência, Chris W.J. van der Weijden, Philipp Mohr, Joyce van Sluis, Johannes H. van Snick, Riemer H.J.A. Slart, Rudi A.J.O. Dierckx, Adriaan A. Lammertsma, Charalampos Tsoumpas
Visual Abstract
-
The Value of 68Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Jingyan Shi, Danyan Li, Mengxia Chen, Yao Fu, Shan Peng, Qing Zhang, Jing Liang, Qun Lu, Jiaming Lu, Shuyue Ai, Feng Wang, Xuefeng Qiu, Hongqian Guo
Visual Abstract
-
68Ga-FAPI PET/CT as an Alternative to 18F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Ertan Sahin, Tulay Kus, Alper Aytekin, Evren Uzun, Umut Elboga, Latif Yilmaz, Yusuf B. Cayirli, Merve Okuyan, Vuslat Cimen, Ufuk Cimen
Visual Abstract
-
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T. Kim, Rachelle K. Saelee, Amanda Morley, Roxanna Juarez, Courtney Lawhn-Heath, Yingbing Wang, Ivan de Kouchkovsky, Thomas A. Hope
Visual Abstract
-
Strong Correlation Between SUVmax on PSMA PET/CT and Numeric Drop-In γ-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Anne-Claire Berrens, Malou A. Sorbi, Maarten L. Donswijk, Hilda A. de Barros, Samaneh Azargoshasb, Matthias N. van Oosterom, Daphne D.D. Rietbergen, Elise M. Bekers, Henk G. van der Poel, Fijs W.B. van Leeuwen, Pim J. van Leeuwen
Visual Abstract
-
68Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression J Nucl. Med. (IF 9.3) Pub Date : 2024-03-07 Li, C., Chen, Q., Tian, Y., Chen, J., Xu, K., Xiao, Z., Zhong, J., Wu, J., Wen, B., He, Y.
Visual Abstract
-
Promising Candidate Prognostic Biomarkers in [18F]FDG PET Images: Evaluation in Independent Cohorts of Non–Small Cell Lung Cancer Patients J Nucl. Med. (IF 9.3) Pub Date : 2024-03-07 Narinée Hovhannisyan-Baghdasarian, Marie Luporsi, Nicolas Captier, Christophe Nioche, Vesna Cuplov, Erwin Woff, Nadia Hegarat, Alain Livartowski, Nicolas Girard, Irène Buvat, Fanny Orlhac
Visual Abstract
-
Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T J Nucl. Med. (IF 9.3) Pub Date : 2024-03-07 Philipp E. Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, Hubert Kübler, Sebastian E. Serfling, Takahiro Higuchi, Wiebke Schlötelburg, Kerstin Michalski, Andrei Gafita, Steven P. Rowe, Martin G. Pomper, Andreas K. Buck, Rudolf A. Werner
Visual Abstract
-
The Accomplishments and Legacy of Saul Hertz, MD J Nucl. Med. (IF 9.3) Pub Date : 2024-03-07 Greenspan, B. S., Hofman, M. S., Buscombe, J.
The early history of the use of radioactive iodine (RAI) is complicated and interesting, and also difficult to discover, especially since several histories have presented inaccurate content. This article is a comprehensive review of the accomplishments of Saul Hertz. Extensive use of primary-source verification has clarified several issues, including the question of whether Hertz alone conceived and
-
Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Ziping Liu, Joyce C. Mhlanga, Huitian Xia, Barry A. Siegel, Abhinav K. Jha
Reliable performance of PET segmentation algorithms on clinically relevant tasks is required for their clinical translation. However, these algorithms are typically evaluated using figures of merit (FoMs) that are not explicitly designed to correlate with clinical task performance. Such FoMs include the Dice similarity coefficient (DSC), the Jaccard similarity coefficient (JSC), and the Hausdorff distance
-
Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with 161Tb and 177Lu: A Comparative Study J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Nadine Holzleitner, Tatjana Cwojdzinski, Roswitha Beck, Nicole Urtz-Urban, Colin C. Hillhouse, Pascal V. Grundler, Nicholas P. van der Meulen, Zeynep Talip, Stijn Ramaekers, Michiel Van de Voorde, Bernard Ponsard, Angela Casini, Thomas Günther
To elucidate potential benefits of the Auger-electron–emitting radionuclide 161Tb, we compared the preclinical performance of the gastrin-releasing peptide receptor antagonists RM2 (DOTA-Pip5-d-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) and AMTG (α-Me-Trp8-RM2), each labeled with both 177Lu and 161Tb. Methods: 161Tb/177Lu labeling (90°C, 5 min) and cell-based experiments (PC-3 cells) were
-
It’s a Trap! Aldolase-Prescribed C4 Deoxyradiofluorination Affords Intracellular Trapping and the Tracing of Fructose Metabolism by PET J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Alexia Kirby, Dominic Graf, Mojmír Suchý, Nicholas D. Calvert, Thomas A. Charlton, Robert N. Ben, Christina L. Addison, Adam Shuhendler
Fructose metabolism has been implicated in various diseases, including metabolic disorders, neurodegenerative disorders, cardiac disorders, and cancer. However, the limited availability of a quantitative imaging radiotracer has hindered its exploration in pathology and diagnostic imaging. Methods: We adopted a molecular design strategy based on the catalytic mechanism of aldolase, a key enzyme in fructolysis
-
Triggered Seizures for Ictal SPECT Imaging: A Case Series and Feasibility Study J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Sabry L. Barlatey, Camille G. Mignardot, Cecilia Friedrichs-Maeder, Kaspar Schindler, Roland Wiest, Andreas Nowacki, Matthias Haenggi, Werner J. Z’Graggen, Claudio Pollo, Axel Rominger, Thomas Pyka, Maxime O. Baud
Ictal SPECT is an informative seizure imaging technique to tailor epilepsy surgery. However, capturing the onset of unpredictable seizures is a medical and logistic challenge. Here, we sought to image planned seizures triggered by direct stimulation of epileptic networks via stereotactic electroencephalography (sEEG) electrodes. Methods: In this case series of 3 adult participants with left temporal
-
First-in-Human Study of 18F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Lindsey R. Drake, Yanjun Wu, Mika Naganawa, Ruth Asch, Chao Zheng, Soheila Najafzadeh, Richard Pracitto, Marcel Lindemann, Songye Li, Jim Ropchan, David Labaree, Paul R. Emery, Mark Dias, Shannan Henry, Nabeel Nabulsi, David Matuskey, Ansel T. Hillmer, Jean-Dominique Gallezot, Richard E. Carson, Zhengxin Cai, Yiyun Huang
PET imaging of synaptic vesicle glycoprotein 2A allows for noninvasive quantification of synapses. This first-in-human study aimed to evaluate the kinetics, test–retest reproducibility, and extent of specific binding of a recently developed synaptic vesicle glycoprotein 2A PET ligand, (R)-4-(3-(18F-fluoro)phenyl)-1-((3-methylpyridin-4-yl)methyl)pyrrolidine-2-one (18F-SynVesT-2), with fast brain kinetics
-
One-Year Longitudinal Changes in Tau Accumulation on [18F]PI-2620 PET in the Alzheimer Spectrum J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Minyoung Oh, Seung Jun Oh, Sang Ju Lee, Jungsu S. Oh, Seung Yeon Seo, Soorack Ryu, Jee Hoon Roh, Jae-Hong Lee, Jae Seung Kim
We investigated the longitudinal changes in cortical tau accumulation and their association with cognitive decline in patients in the Alzheimer disease (AD) continuum using 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5c']dipyridine ([18F]PI-2620) PET. Methods: We prospectively enrolled 52 participants (age, 69.7 ± 8.4 y; 18 men and 34 women): 7 with normal cognition, 28 with mild cognitive impairment
-
Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Ralph Buchert, Balazs Szabo, Akos Kovacs, Thomas Buddenkotte, Franziska Mathies, Amir Karimzadeh, Wencke Lehnert, Susanne Klutmann, Attila Forgacs, Ivayla Apostolova
This study evaluated the potential to reduce the scan duration in dopamine transporter (DAT) SPECT when using a second-generation multiple-pinhole (MPH) collimator designed for brain SPECT with improved count sensitivity and improved spatial resolution compared with parallel-hole and fanbeam collimators. Methods: The retrospective study included 640 consecutive clinical DAT SPECT studies that had been
-
Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Andrea Farolfi, Wesley R. Armstrong, Loic Djaileb, Andrei Gafita, Masatoshi Hotta, Martin Allen-Auerbach, Lena M. Unterrainer, Wolfgang P. Fendler, Matthew Rettig, Matthias Eiber, Michael S. Hofman, Boris Hadaschik, Ken Herrmann, Johannes Czernin, Jeremie Calais, Matthias R. Benz
177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy effectively treats metastatic castration-resistant prostate cancer. Patients requiring treatment, and consequently the number of theranostic centers, are expected to increase significantly after Food and Drug Administration and European Medicines Agency approval. This requires standardization or harmonization among theranostic
-
First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Alexander Dierks, Alexander Gäble, Andreas Rinscheid, Georgine Wienand, Christian H. Pfob, Malte Kircher, Johanna S. Enke, Tilman Janzen, Marianne Patt, Martin Trepel, Dorothea Weckermann, Ralph A. Bundschuh, Constantin Lapa
We recently published the first dosimetry data, to our knowledge, for the radioligand therapy agent 177Lu-rhPSMA-10.1, providing an intrapatient comparison with 177Lu-PSMA-I&T in patients with metastatic prostate cancer. Here, we report efficacy and safety findings from these patients. Methods: Four consecutive patients with prostate-specific membrane antigen (PSMA)–positive metastatic prostate cancer
-
Prostate-Specific Membrane Antigen–Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Melline G.M. Schilham, Diederik M. Somford, Heidi V.N. Küsters-Vandevelde, Rick Hermsen, Jean Paul A. van Basten, Robert J. Hoekstra, Tom W.J. Scheenen, Martin Gotthardt, J.P. Michiel Sedelaar, Mark Rijpkema
Prostate-specific membrane antigen (PSMA)–targeted radioguided surgery (RGS) aims to optimize the peroperative detection and removal of PSMA-avid lymph node (LN) metastases (LNMs) and has been described in patients with recurrent prostate cancer (PCa). In newly diagnosed PCa patients undergoing pelvic LN dissections, PSMA RGS could guide the urologist toward PSMA-expressing LNMs as identified on preoperative
-
Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Suraiya Dubash, Tara D. Barwick, Kasia Kozlowski, Andrea G. Rockall, Sairah Khan, Sameer Khan, Siraj Yusuf, Angela Lamarca, Juan W. Valle, Richard A. Hubner, Mairéad G. McNamara, Andrea Frilling, Tricia Tan, Florian Wernig, Jeannie Todd, Karim Meeran, Bhavesh Pratap, Saleem Azeem, Michael Huiban, Nicholas Keat, Jingky P. Lozano-Kuehne, Eric O. Aboagye, Rohini Sharma
There is a clinical need for 18F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [68Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility. We have shown that [18F]fluoroethyl-triazole-[Tyr3]-octreotate ([18F]FET-βAG-TOCA) has favorable dosimetry and biodistribution. As a step toward clinical implementation, we conducted
-
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Yadav, S., Lawhn-Heath, C., Paciorek, A., Lindsay, S., Mirro, R., Bergsland, E. K., Hope, T. A.
Posttreatment imaging of -emissions after peptide receptor radionuclide therapy (PRRT) can be used to perform quantitative dosimetry as well as assessment response using qualitative measures. We aimed to assess the impact of qualitative posttreatment imaging on the management of patients undergoing PRRT. Methods: In this retrospective study, we evaluated 100 patients with advanced well-differentiated
-
Effectiveness of 225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Anjong Florence Tikum, Jessica P. Ketchemen, Alireza Doroudi, Anand K. Nambisan, Hanan Babeker, Fabrice Ngoh Njotu, Humphrey Fonge
Eighty percent of colorectal cancers (CRCs) overexpress epidermal growth factor receptor (EGFR). Kirsten rat sarcoma viral oncogene (KRAS) mutations are present in 40% of CRCs and drive de novo resistance to anti-EGFR drugs. BRAF oncogene is mutated in 7%–10% of CRCs, with even worse prognosis. We have evaluated the effectiveness of [225Ac]Ac-macropa-nimotuzumab in KRAS mutant and in KRAS wild-type
-
Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Liang Zhao, Yizhen Pang, Jianyang Fang, Jianhao Chen, Yangfan Zhou, Long Sun, Hua Wu, Zhide Guo, Qin Lin, Haojun Chen
Extensive research has been conducted on radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) and p-Cl-Phe-cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH2 (LM3) peptides for imaging of FAP and somatostatin receptor 2 (SSTR2)–positive tumors. In this study, we designed and synthesized a FAPI-LM3 heterobivalent molecule radiolabeled with 68Ga and evaluated its effectiveness
-
First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Randy Yeh, Joseph A. O’Donoghue, Vetri Sudar Jayaprakasam, Audrey Mauguen, Ryan Min, Sue Park, Julia P. Brockway, Jacqueline F. Bromberg, W Iris Zhi, Mark E. Robson, Rachel Sanford, Shanu Modi, Brian J. Agnew, Serge K. Lyashchenko, Jason S. Lewis, Gary A. Ulaner, Brian M. Zeglis
Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic approach that has been traditionally used to radiolabel these antibodies yields poorly defined and heterogeneous products with suboptimal in vivo performance. Here, we describe a first-in-human PET study on patients with HER2-positive
-
Diagnostic Performance of 68Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Alexander Light, Stefan Lazic, Kate Houghton, Max Bayne, Martin J. Connor, Henry Tam, Hashim U. Ahmed, Taimur T. Shah, Tara D. Barwick
For men with prostate cancer who develop biochemical failure after radiotherapy, European guidelines recommend reimaging with 68Ga-PSMA-11 PET/CT and multiparametric MRI (mpMRI). However, the accuracy of 68Ga-PSMA-11 PET/CT for detecting intraprostatic recurrences is unclear, both with and without mpMRI. Methods: A single-center retrospective study of a series of patients investigated for radiorecurrence
-
Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Lukas Kessler, Kim M. Pabst, Francesco Barbato, Helena Lanzafame, Stefan Kasper, Michael Nader, Claudia Kesch, Bastian von Tresckow, Hubertus Hautzel, Clemens Aigner, Martin Glas, Martin Stuschke, Sherko Kümmel, Philipp Harter, Celine Lugnier, Waldemar Uhl, Boris Hadaschik, Viktor Grünwald, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler
To assess the diagnostic accuracy of 68Ga-labeled fibroblast activation protein inhibitor (FAPI) and 18F-labeled FDG PET for the detection of various tumors, we performed a head-to-head comparison of both imaging modalities across a range of tumor entities as part of our ongoing 68Ga-FAPI PET observational trial. Methods: The study included 115 patients with 8 tumor entities who received imaging with
-
Imaging of Tumor Stroma Using 68Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Bingxin Gu, Ziyi Yang, Xinyue Du, Xiaoping Xu, Xiaomin Ou, Zuguang Xia, Qing Guan, Silong Hu, Zhongyi Yang, Shaoli Song
The low detection rate of primary tumors by current diagnostic techniques remains a major concern for patients with head and neck cancer of unknown primary (HNCUP). Therefore, in this study, we aimed to investigate the potential role of 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT compared with 18F-FDG PET/CT for the detection of primary tumors of HNCUP. Methods: In this
-
Molecular Imaging of Acute Graft-Versus-Host Disease J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Chiara Bernardi, Valentina Garibotto, Behnaz Mobashwera, Robert S. Negrin, Israt S. Alam, Federico Simonetta
Noninvasive molecular imaging of acute graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation has great potential to detect GvHD at the early stages, aid in grading of the disease, monitor treatment response, and guide therapeutic decisions. Although the specificity of currently available tracers appears insufficient for clinical GvHD diagnosis, recently, several
-
The Current and Future Roles of Precision Oncology in Advanced Breast Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Heather Jacene, Eric Dietsche, Jennifer Specht
Breast cancer is a common but heterogeneous disease characterized by several biologic features, including tumor grade, hormone receptor status, human epidermal growth factor receptor 2 status, and gene expression assays. These biologic and genomic features drive treatment decisions. In the advanced disease setting, inter- and intrapatient tumor heterogeneity is increasingly recognized as a challenge
-
Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients J Nucl. Med. (IF 9.3) Pub Date : 2024-03-01 Strosberg, J. R., Al-Toubah, T., El-Haddad, G., Reidy Lagunes, D., Bodei, L.
Most well-differentiated neuroendocrine tumors (NETs) express high levels of somatostatin receptors, particularly subtypes 2 and 5. Somatostatin analogs (SSAs) bind to somatostatin receptors and are used for palliation of hormonal syndromes and control of tumor growth. The long-acting SSAs octreotide long-acting release and lanreotide are commonly used in the first-line metastatic setting because of
-
Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma J Nucl. Med. (IF 9.3) Pub Date : 2024-02-29 Fanching Lin, Renee Clift, Takeru Ehara, Hayato Yanagida, Steven Horton, Alain Noncovich, Matt Guest, Daniel Kim, Katrina Salvador, Samantha Richardson, Terra Miller, Guangzhou Han, Abhijit Bhat, Kenneth Song, Gary Li
Visual Abstract
-
Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [177Lu]Lu-PSMA-617 Therapy J Nucl. Med. (IF 9.3) Pub Date : 2024-02-29 Deni Hardiansyah, Elham Yousefzadeh-Nowshahr, Felix Kind, Ambros J. Beer, Juri Ruf, Gerhard Glatting, Michael Mix
Visual Abstract
-
Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and 11C-Labeled Radioligands That Avoid Radiometabolite Contamination J Nucl. Med. (IF 9.3) Pub Date : 2024-02-29 Meijuan Jiang, Shiyu Tang, Madeline D. Jenkins, Adrian C. Lee, Bruny Kenou, Carson Knoer, Jose Montero Santamaria, Shawn Wu, Jeih-San Liow, Sami S. Zoghbi, Paolo Zanotti-Fregonara, Robert B. Innis, Sanjay Telu, Victor W. Pike
Visual Abstract
-
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients J Nucl. Med. (IF 9.3) Pub Date : 2024-02-29 Dianne Bosch, Kim J.M. van der Velden, Irma M. Oving, Dirk N.J. Wyndaele, Leo E. Weijs, W. Dick van Schelven, Wim J.G. Oyen, Erik T. te Beek, Addy C.M. van de Luijtgaarden, Diederik M. Somford, James Nagarajah, Rick Hermsen, Niven Mehra, Winald R. Gerritsen, Maarten J. van der Doelen, Inge M. van Oort
Visual Abstract
-
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study J Nucl. Med. (IF 9.3) Pub Date : 2024-02-29 Christopher Eigler, Lisa McDougall, Andreas Bauman, Peter Bernhardt, Michael Hentschel, Kristine A. Blackham, Guillaume Nicolas, Melpomeni Fani, Damian Wild, Dominik Cordier
Visual Abstract
-
Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT J Nucl. Med. (IF 9.3) Pub Date : 2024-02-29 Kevin H. Leung, Steven P. Rowe, Moe S. Sadaghiani, Jeffrey P. Leal, Esther Mena, Peter L. Choyke, Yong Du, Martin G. Pomper
Visual Abstract
-
Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-02-29 Mohamed El Fakiri, Nawal Ayada, Marius Müller, Lars Hvass, Teodor H. Gamzov, Anne Skovsbo Clausen, Nicolas M. Geis, Nils Steinacker, Ellinor Hansson, Sture Lindegren, Emma Aneheim, Holger Jensen, Ann-Christin Eder, Andreas I. Jensen, Christian B.M. Poulie, Andreas Kjaer, Matthias Eder, Matthias M. Herth
Visual Abstract
-
Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard J Nucl. Med. (IF 9.3) Pub Date : 2024-02-22 Guiyu Li, Wenhui Ma, Xiang Li, Weidong Yang, Zhiyong Quan, Taoqi Ma, Junling Wang, Yunya Wang, Fei Kang, Jing Wang
Visual Abstract
-
Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council J Nucl. Med. (IF 9.3) Pub Date : 2024-02-22 Riemer H.J.A. Slart, Frank M. Bengel, Cigdem Akincioglu, Jamieson M. Bourque, Wengen Chen, Marc R. Dweck, Marcus Hacker, Saurabh Malhotra, Edward J. Miller, Matthieu Pelletier-Galarneau, René R.S. Packard, Thomas H. Schindler, Richard L. Weinberg, Antti Saraste, Piotr J. Slomka
Digital PET/CT systems with a long axial field of view have become available and are emerging as the current state of the art. These new camera systems provide wider anatomic coverage, leading to major increases in system sensitivity. Preliminary results have demonstrated improvements in image quality and quantification, as well as substantial advantages in tracer kinetic modeling from dynamic imaging
-
Clinical Evaluation of Deep Learning for Tumor Delineation on 18F-FDG PET/CT of Head and Neck Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-02-22 David G. Kovacs, Claes N. Ladefoged, Kim F. Andersen, Jane M. Brittain, Charlotte B. Christensen, Danijela Dejanovic, Naja L. Hansen, Annika Loft, Jørgen H. Petersen, Michala Reichkendler, Flemming L. Andersen, Barbara M. Fischer
Visual Abstract
-
MIRD Pamphlet No. 29: MIRDy90—A 90Y Research Microsphere Dosimetry Tool J Nucl. Med. (IF 9.3) Pub Date : 2024-02-22 Harry Marquis, Juan C. Ocampo Ramos, Lukas M. Carter, Pat Zanzonico, Wesley E. Bolch, Richard Laforest, Adam L. Kesner
90Y-microsphere radioembolization has become a well-established treatment option for liver malignancies and is one of the first U.S. Food and Drug Administration–approved unsealed radionuclide brachytherapy devices to incorporate dosimetry-based treatment planning. Several different mathematical models are used to calculate the patient-specific prescribed activity of 90Y, namely, body surface area
-
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma J Nucl. Med. (IF 9.3) Pub Date : 2024-02-22 Hofman, M. S., Tran, B., Feldman, D. R., Pokorska-Bocci, A., Pichereau, S., Wessen, J., Haskali, M. B., Sparks, R. B., Vlasyuk, O., Galetic, I.
Visual Abstract
-
The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease J Nucl. Med. (IF 9.3) Pub Date : 2024-02-15 Amar U. Kishan, Shankar Siva, Michael S. Hofman, James Nagarajah, Ana P. Kiess, Phuoc Tran, Jeremie Calais
There is a growing understanding of the oligometastatic disease state, characterized by the presence of 5 or fewer lesions. Advanced molecular imaging techniques, such as prostate-specific membrane antigen PET, refines the ability to detect oligometastatic recurrences (oligorecurrences) early. These developments have led to the exploration of metastasis-directed therapy (MDT) in oligorecurrent disease
-
PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non–Small Cell Lung Cancer Treated with Curative Radiotherapy J Nucl. Med. (IF 9.3) Pub Date : 2024-02-15 Vincent Bourbonne, Moncef Morjani, Olivier Pradier, Mathieu Hatt, Vincent Jaouen, Solène Querellou, Dimitris Visvikis, François Lucia, Ulrike Schick
Visual Abstract
-
Effectiveness of 225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models J Nucl. Med. (IF 9.3) Pub Date : 2024-02-15 Tikum, A. F., Ketchemen, J. P., Doroudi, A., Nambisan, A. K., Babeker, H., Njotu, F. N., Fonge, H.
Visual Abstract
-
Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies J Nucl. Med. (IF 9.3) Pub Date : 2024-02-08 Hirmas, N., Hamacher, R., Sraieb, M., Kessler, L., Pabst, K. M., Barbato, F., Lanzafame, H., Kasper, S., Nader, M., Kesch, C., von Tresckow, B., Hautzel, H., Aigner, C., Glas, M., Stuschke, M., Kummel, S., Harter, P., Lugnier, C., Uhl, W., Hadaschik, B., Grunwald, V., Siveke, J. T., Herrmann, K., Fendler, W. P.
Visual Abstract
-
Dynamic Human Brain Imaging with a Portable PET Camera: Comparison to a Standard Scanner J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Elizabeth A. Bartlett, Mohammad Lesanpezeshki, Sergey Anishchenko, Ilia Shkolnik, R. Todd Ogden, J. John Mann, David Beylin, Jeffrey M. Miller, Francesca Zanderigo
Portable, cost-effective PET cameras can radically expand the applicability of PET. We present here a within-participant comparison of fully quantified [18F]FDG dynamic scans in healthy volunteers using the standard Biograph mCT scanner and portable CerePET scanner. Methods: Each of 20 healthy volunteers underwent dynamic [18F]FDG imaging with both scanners (1–154 d apart) and concurrent arterial blood
-
Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Kibrom B. Girum, Anne-Ségolène Cottereau, Laetitia Vercellino, Louis Rebaud, Jérôme Clerc, Olivier Casasnovas, Franck Morschhauser, Catherine Thieblemont, Irène Buvat
Baseline [18F]FDG PET/CT radiomic features can improve the survival prediction in patients with diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to investigate whether characterizing tumor locations relative to the spleen location in baseline [18F]FDG PET/CT images predicts survival in patients with DLBCL and improves the predictive value of total metabolic tumor volume (TMTV) and
-
Early-Frame [18F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [15O]Water Gold Standard J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Fettahoglu, A., Zhao, M., Khalighi, M., Vossler, H., Jovin, M., Davidzon, G., Zeineh, M., Boada, F., Mormino, E., Henderson, V. W., Moseley, M., Chen, K. T., Zaharchuk, G.
Cerebral blood flow (CBF) may be estimated from early-frame PET imaging of lipophilic tracers, such as amyloid agents, enabling measurement of this important biomarker in participants with dementia and memory decline. Although previous methods could map relative CBF, quantitative measurement in absolute units (mL/100 g/min) remained challenging and has not been evaluated against the gold standard method
-
Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Yingfang He, Stefanie D. Krämer, Uwe Grether, Matthias B. Wittwer, Ludovic Collin, Bernd Kuhn, Andreas Topp, Dominik Heer, Fionn O’Hara, Michael Honer, Anto Pavlovic, Hans Richter, Martin Ritter, Didier Rombach, Claudia Keller, Luca Gobbi, Linjing Mu
This study aimed to evaluate (R)-[18F]YH134 as a novel PET tracer for imaging monoacylglycerol lipase (MAGL). Considering the ubiquitous expression of MAGL throughout the whole body, the impact of various MAGL inhibitors on (R)-[18F]YH134 brain uptake and its application in brain–periphery crosstalk were explored. Methods: MAGL knockout and wild-type mice were used to evaluate (R)-[18F]YH134 in in vitro
-
Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical Disease in Inflammatory Arthritis J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Puuvuori, E., Shen, Y., Hulsart-Billstrom, G., Mitran, B., Zhang, B., Cheung, P., Wegrzyniak, O., Ingvast, S., Persson, J., Stahl, S., Korsgren, O., Lofblom, J., Wermeling, F., Eriksson, O.
Rheumatoid arthritis (RA) is the most common inflammatory joint disease, and early diagnosis is key for effective disease management. CD69 is one of the earliest cell surface markers seen at the surface of activated immune cells, and CD69 is upregulated in synovial tissue in patients with active RA. In this study, we evaluated the performance of a CD69-targeting PET agent, [68Ga]Ga-DOTA-ZCAM241, for
-
Toward Quantitative Multisite Preclinical Imaging Studies in Acute Myocardial Infarction: Evaluation of the Immune-Fibrosis Axis J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Maja Strunk, Gyu Seong Heo, Annika Hess, Hannah Luehmann, Tobias L. Ross, Robert J. Gropler, Frank M. Bengel, Yongjian Liu, James T. Thackeray
The immune-fibrosis axis plays a critical role in cardiac remodeling after acute myocardial infarction. Imaging approaches to monitor temporal inflammation and fibroblast activation in mice have seen wide application in recent years. However, the repeatability of quantitative measurements remains challenging, particularly across multiple imaging centers. We aimed to determine reproducibility of quantitative
-
Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous Wave-Free Ratio Assessment Through Quantitative [15O]H2O PET Myocardial Perfusion Imaging J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Ruben W. de Winter, Pepijn A. van Diemen, Stefan P. Schumacher, Ruurt A. Jukema, Yvemarie B.O. Somsen, Roel Hoek, Albert C. van Rossum, Jos W.R. Twisk, Guus A. de Waard, Alexander Nap, Pieter G. Raijmakers, Roel S. Driessen, Paul Knaapen, Ibrahim Danad
In patients evaluated for obstructive coronary artery disease (CAD), guidelines recommend using either fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) to guide coronary revascularization decision-making. The hemodynamic significance of lesions with discordant FFR and iFR measurements is debated. This study compared [15O]H2O PET–derived absolute myocardial perfusion between vessels
-
Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Martijn E.H.M. Wagemans, Britt Kunnen, Martina Stella, Rob van Rooij, Maarten Smits, Rutger Bruijnen, Marnix G.E.H. Lam, Hugo W.A.M. de Jong, Arthur J.A.T. Braat
Our objective was to compare 3 different therapeutic particles used for radioembolization in locally advanced intrahepatic cholangiocarcinoma. Methods: 90Y-glass, 90Y-resin, and 166Ho-labeled poly(l-lactic acid) microsphere prescribed activity was calculated as per manufacturer recommendations. Posttreatment quantitative 90Y PET/CT and quantitative 166Ho SPECT/CT were used to determine tumor-absorbed
-
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Etienne Garin, Lambros Tselikas, Boris Guiu, Julia Chalaye, Yan Rolland, Thierry de Baere, Eric Assenat, Vania Tacher, Xavier Palard, Desirée Déandreis, Denis Mariano-Goulart, Giuliana Amaddeo, Karim Boudjema, Antoine Hollebecque, Mohamad Azhar Meerun, Helen Regnault, Eric Vibert, Boris Campillo-Gimenez, Julien Edeline
Interim analysis of the DOSISPHERE-01 study demonstrated a strong improvement in response and overall survival (OS) on using 90Y-loaded glass microspheres with personalized dosimetry compared with standard dosimetry in patients with nonoperable locally advanced hepatocellular carcinoma. This report sought to provide a long-term analysis of OS. Methods: In this phase II study (ClinicalTrials.gov identifier
-
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network J Nucl. Med. (IF 9.3) Pub Date : 2024-02-01 Laure Al Mansour, Louis De Mestier, Magalie Haissaguerre, Pauline Afchain, Julien Hadoux, Thierry Lecomte, David Morland, Anne Segolene Cottereau, Ophelie De Rycke, Ghoufrane Tlili, Jérémie Tordo, Marc Janier, Agathe Deville, Thomas Walter
A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal neuroendocrine tumors (SI-NETs). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) has shown its efficacy in patients with progressive SI-NETs. However, because of specific tissue characteristics of desmoplastic MMs, we hypothesize that these lesions may be refractory to 177Lu-DOTATATE PRRT. Methods: